#United States #South San Francisco #IDEAYA #darovasertib #IDE849

IDEAYA Biosciences to Present at ESMO 2026

IDEAYA Biosciences, a leader in precision medicine focused on oncology, has revealed its intentions to present three significant research posters during the European Society of Medical Oncology (ESMO) 2026 Conference, which is scheduled to be held from October 23-27 in Madrid, Spain. This year's presentations will delve into the promising developments in their clinical research pipeline, specifically highlighting the ongoing trials of Darovasertib in uveal melanoma.

Among these trials, IDEAYA is advancing the Phase 2/3 OptimUM-02 trial, which targets HLAA201-negative metastatic uveal melanoma (mUM). Additionally, the Phase 2 OptimUM-01 trial focuses on HLAA201-positive mUM, while the Phase 2 OptimUM-09 trial evaluates darovasertib's effectiveness in the neoadjuvant setting for primary uveal melanoma treatment. Each of these studies aims to shed light on the potential of Darovasertib as a vital treatment option for patients grappling with this aggressive form of cancer.

Dr. Darrin Beaupre, the Chief Medical Officer at IDEAYA, expressed enthusiasm about the opportunity to showcase their progress at such a prestigious event. He stated, "We are excited to showcase the breadth of our pipeline progress at this year’s ESMO Congress. The data from our ongoing trials strengthen our belief in darovasertib's potential to become an essential new treatment for uveal melanoma patients across their treatment journey."

In collaboration with Hengrui Pharma, there is also a spotlight on the clinical trial results for IDE849 (SHR-4849), a novel therapy being evaluated in patients with small cell lung carcinoma (SCLC) and neuroendocrine carcinomas (NECs) in a Phase 1 study conducted in China.

IDEAYA’s Presentation Overview

1. 2092P - Neoadjuvant Darovasertib in Primary Uveal Melanoma Follow-Up Data from the Phase 2 OptimUM-09 Study
- Presenter: Mark Shackleton, MBBS, PhD, FRACP, Alfred Hospital, Melbourne, Australia

2. 2104P - Darovasertib Combined with Crizotinib Versus Investigator's Choice as First-Line Treatment for HLA-A2 Negative Metastatic Uveal Melanoma (OptimUM-02) A Subgroup Analysis
- Presenter: Sophie Piperno-Neumann, MD, PhD, Institute Curie, Paris, France

3. 2086P - Darovasertib and Crizotinib for HLA-A02-Positive Metastatic Uveal Melanoma Results from the Phase 2 OptimUM-01 Study*
- Presenter: Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, Tennessee, USA

These presentations aim to empower the clinical community with new data and insights that could potentially change practices in treating uveal melanoma.

In addition to IDEAYA’s own findings, Hengrui Pharma's presentation (3815P) will focus on the long-term results from the Phase 1 study of SHR-4849 in relapsed SCLC and other NECs. This new therapeutic approach is poised to offer hope for patients with limited treatment options.

About IDEAYA Biosciences

IDEAYA is at the forefront of precision medicine in oncology, dedicated to developing transformative therapies to address significant unmet medical needs in cancer treatment. Their comprehensive strategy integrates small-molecule drug discovery with structural biology and bioinformatics, aimed at fostering the development of first-in-class targeted therapies through the identification and validation of translational biomarkers.

The firm has diligently built a robust pipeline of therapies centered on synthetic lethality and antibody-drug conjugates, including bispecifics, striving to enhance clinical outcomes for cancer patients. IDEAYA’s commitment to innovation and excellence in oncology is evident as they continue to pave the way forward.

In conclusion, the upcoming ESMO 2026 meeting remains a critical platform for sharing vital advancements in cancer research, and IDEAYA's presentations promise to contribute significant insights that could impact patient care positively. The firm’s ongoing collaboration with trusted partners such as Hengrui Pharma further exemplifies their dedication to combating cancer through cutting-edge innovation.